Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

How to transform the medical organization in specialty care to drive best-in-class patient value

Ipsen publishes strong Q1 2022 results

Ukraine situation: What Ipsen is doing

Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer HealthCare business